Alector, Inc.ALEC

時価総額

$1.3億

PER

神経変性疾患治療薬の開発の有力企業。血液脳関門輸送のABC技術と毒性タンパク除去・蛋白補充を目指す候補薬群を展開。2024年1月19日の公募で7,110万ドル調達、AbbVieやGSKとの提携あり。米国拠点で臨床開発を推進。

	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Cash and cash equivalents	90	50	329	154	75	33
Marketable securities	263	363	406	559	474	380
Prepaid expenses and other current assets	4	8	7	11	17	11
Total current assets	357	422	750	726	566	425
Property and equipment, net	34	30	27	26	22	17
Operating lease right-of-use assets	28	32	31	28	25	20
Restricted cash	1	1	2	2	2	2
Other assets	1	3	6	6	7	5
Total assets	422	488	815	788	622	468
Accounts payable	0	3	5	4	4	2
Accrued Clinical Supply Cost	7	11	9	6	5	7
Accrued liabilities	18	23	27	28	30	29
Deferred revenue, current portion	30	24	91	48	83	24
Collaboration Payable	-	-	-	-	8	6
Contract with Customer, Refund Liability, Current	-	-	-	-	39	49
Operating Lease, Liability, Current	7	8	8	8	8	9
Total current liabilities	62	68	140	94	178	125
Deferred revenue, long-term portion	123	108	334	443	211	172
Long-term debt	-	-	-	-	-	9
Contract with Customer, Refund Liability, Noncurrent	-	-	-	-	67	9
Operating Lease, Liability, Noncurrent	41	44	40	35	30	24
Other long-term liabilities	0	0	0	1	1	1
Total liabilities	227	221	514	573	488	342
Common Stock, Value, Issued	0	0	0	0	0	0
Additional paid-in capital	414	677	748	799	844	956
Accumulated other comprehensive income	0	1	-1	-5	0	0
Accumulated deficit	-220	-410	-446	-580	-710	-829
Total stockholders' equity	195	268	301	214	134	127
Total liabilities and stockholders' equity	422	488	815	788	622	468